WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 9, 2018 to discuss its 2017 operating results. Management also will provide a brief update on the business.
Conference Call Information
To access the live call by
phone, dial 719-325-4917; the conference ID is 5734226. The call may
also be accessed through the Investors section of the Company’s website, www.immunogen.com.
Following the webcast, a replay of the call will be available at the
same location through February 23, 2018.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics using
its proprietary ADC technology. The Company’s lead product candidate,
mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in
combination regimens for earlier-stage disease. ImmunoGen has three
additional clinical-stage product candidates, two of which are being
developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC
technology is also used in Roche's marketed product, Kadcyla®,
and in programs in development by Amgen, Bayer, Biotest, CytomX,
Debiopharm, Lilly, Novartis, Sanofi and Takeda. More information about
the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.